1,745
Views
3
CrossRef citations to date
0
Altmetric
Cardiovascular

Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US

, , , , , & show all
Pages 1365-1374 | Received 07 Aug 2020, Accepted 03 Sep 2020, Published online: 29 Sep 2020

Figures & data

Figure 1. Patient disposition. AF, atrial fibrillation; VTE, venous thromboembolism. Note. 1. Patients initiated on treatment with both rivaroxaban and apixaban on the index date were classified as apixaban, and subsequently excluded (n = 16).

Figure 1. Patient disposition. AF, atrial fibrillation; VTE, venous thromboembolism. Note. 1. Patients initiated on treatment with both rivaroxaban and apixaban on the index date were classified as apixaban, and subsequently excluded (n = 16).

Table 1. Baseline demographics and clinical characteristics – unweighted and weighted rivaroxaban and apixaban cohorts.

Table 2. NVAF-related comorbidities and risk factors for stroke/systemic embolism and major bleeding – unweighted and weighted rivaroxaban and apixaban cohorts.

Table 3. All-cause healthcare resource utilization of the rivaroxaban and apixaban cohorts – up to 18 and 24 months follow-up.

Table 4. Healthcare cost components of the rivaroxaban and apixaban cohorts – up to 18 and 24 months follow-up.

Supplemental material

Supplemental Material: Table 2

Download MS Word (13.3 KB)

Supplemental Material: Table 1

Download MS Word (13.2 KB)